One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.
XPH charges less and pays a higher yield, but IBB manages over 20 times the assets across a far broader set of research-driven biotech names.
Fewer holdings, a higher fee, and a shallower drawdown set these two biotech funds apart in ways that could matter for long-term investors.
IHE offers lower costs and higher income through a concentrated play on established drugmakers, while IBB provides broader exposure to 243 biotech firms with higher volatility.
Smart Beta ETF report for IBB
Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.
The fund's $10.50 billion portfolio saw $219.7 million in gross trading, all of it selling, with Gilead Sciences the largest sale at $18.6 million.
IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.
VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.
iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.
XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.
Smart Beta ETF report for IBB
This is the newest page. Registered accounts read further back.